| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/18/2023 | — | TD Cowen | Downgrades | Outperform → Market Perform | |
| 07/26/2023 | 693.65% | Morgan Stanley | $2 → $10 | Maintains | Equal-Weight |
| 02/15/2023 | 58.73% | Morgan Stanley | $4 → $2 | Maintains | Equal-Weight |
| 11/16/2022 | 98.41% | Chardan Capital | → $2.5 | Downgrades | Buy → Neutral |
| 09/09/2022 | 217.46% | Morgan Stanley | $5 → $4 | Maintains | Equal-Weight |
| 08/24/2022 | 296.83% | Morgan Stanley | $6 → $5 | Maintains | Equal-Weight |
| 08/15/2022 | 296.83% | Chardan Capital | $12 → $5 | Maintains | Buy |
| 11/02/2021 | 3193.65% | JMP Securities | $44 → $41.5 | Maintains | Market Outperform |
| 11/01/2021 | 852.38% | Chardan Capital | → $12 | Upgrades | Neutral → Buy |
| 06/23/2021 | 2915.87% | JMP Securities | $36 → $38 | Maintains | Market Outperform |
| 06/23/2021 | 2122.22% | Cantor Fitzgerald | → $28 | Initiates Coverage On | → Overweight |
| 05/03/2021 | 931.75% | Morgan Stanley | $14 → $13 | Maintains | Equal-Weight |
| 04/12/2021 | 1328.57% | Jefferies | $11 → $18 | Upgrades | Hold → Buy |
| 01/19/2021 | 1011.11% | Morgan Stanley | $6 → $14 | Maintains | Equal-Weight |
| 12/23/2020 | 2042.86% | JMP Securities | → $27 | Initiates Coverage On | → Outperform |
| 11/11/2020 | 376.19% | Morgan Stanley | $8 → $6 | Maintains | Equal-Weight |
| 05/21/2020 | 534.92% | Morgan Stanley | → $8 | Downgrades | Overweight → Equal-Weight |
| 05/12/2020 | 1566.67% | BMO Capital | $24 → $21 | Maintains | Outperform |
| 05/12/2020 | 376.19% | Jefferies | $18 → $6 | Downgrades | Buy → Hold |
| 04/30/2019 | 1328.57% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 01/29/2019 | 693.65% | Chardan Capital | → $10 | Initiates Coverage On | → Neutral |
What is the target price for Evelo Biosciences (EVLO)?
The latest price target for Evelo Biosciences (NASDAQ: EVLO) was reported by TD Cowen on October 18, 2023. The analyst firm set a price target for $0.00 expecting EVLO to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Evelo Biosciences (EVLO)?
The latest analyst rating for Evelo Biosciences (NASDAQ: EVLO) was provided by TD Cowen, and Evelo Biosciences downgraded their market perform rating.
When is the next analyst rating going to be posted or updated for Evelo Biosciences (EVLO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evelo Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evelo Biosciences was filed on October 18, 2023 so you should expect the next rating to be made available sometime around October 18, 2024.
Is the Analyst Rating Evelo Biosciences (EVLO) correct?
While ratings are subjective and will change, the latest Evelo Biosciences (EVLO) rating was a downgraded with a price target of $0.00 to $0.00. The current price Evelo Biosciences (EVLO) is trading at is $1.26, which is out of the analyst's predicted range.